We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

17 hedge funds and large institutions have $3.16M invested in Moleculin Biotech in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

13% more funds holding

Funds holding: 15 → 17 (+2)

7% more capital inflows, than outflows

Capital inflows: $81.1K | Capital outflows: $75.6K

0.02% more ownership

Funds ownership: 10.42% → 10.43% (+0.02%)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
17
Holders Change
+2
Holders Change %
+13.33%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
–
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
+$34.7K
2
Citadel Advisors
Citadel Advisors
Florida
+$23.2K
3
Envestnet Asset Management
Envestnet Asset Management
Illinois
+$11.6K
4
UBS Group
UBS Group
Switzerland
+$11.6K

Top Sellers

Rank Fund Capital Flow
1
Charles Schwab
Charles Schwab
California
-$46K
2
Two Sigma Advisers
Two Sigma Advisers
New York
-$17K
3
Renaissance Technologies
Renaissance Technologies
New York
-$11.6K
4
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors
North Carolina
-$1K

MBRX Hedge Fund Activity: Q3 2022 in Review

17 of the 5,832 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q3 2022, worth a combined $3.16M — down 27% from $4.32M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new MBRX positions and 2 closed out — a net gain of 2 holders — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Jane Street, opening a new position worth an estimated $34.7K. The largest seller was Charles Schwab, exiting entirely with an estimated $46K sold.

  • 17 institutional investors held Moleculin Biotech (MBRX) as of Q3 2022, up from 15 in Q2 2022.
  • Funds reported $3.16M of Moleculin Biotech stock for Q3 2022, down 27% quarter-over-quarter.
  • 4 funds opened new Moleculin Biotech positions in Q3 2022 and 2 closed out, a net change of +2 holders.
  • The largest Moleculin Biotech buyer in Q3 2022 was Jane Street, an estimated $34.7K added.
  • The largest Moleculin Biotech seller in Q3 2022 was Charles Schwab, an estimated $46K sold.

Based on aggregated 13F filings for Q3 2022.